The Inpact project represents a collaborative research initiative focused on developing innovative peptides that target both cancer cells and pathogenic bacteria. By combining antitumoural and antimicrobial properties within single molecular entities, researchers aim to create a new class of biopharmaceutical drugs. This approach leverages the natural ability of peptides to interact with biological membranes, potentially overcoming some of the limitations faced by conventional therapeutics. The work builds on advances in molecular medicine and peptide engineering, bringing together experts from multiple disciplines to explore how these hybrid molecules can be designed, tested, and refined for future clinical applications.

Central to the Inpact project is the concept of producing peptide chimeras that merge different functional domains into one molecule. These chimeras are designed to recognise and bind to specific targets on cancer cells or bacterial surfaces while also carrying barrier-translocating sequences that help them reach their intended destinations inside cells. The research explores how chemical modifications can enhance stability, selectivity, and potency. This platform technology has the potential to generate entirely new therapeutic options where single agents address complex diseases that involve both malignant cell growth and microbial infection, an area of growing medical need.

The training and staff exchange components of the Inpact programme are fundamental to its mission. Researchers from academic institutions and pharmaceutical companies across different countries participate in structured secondments, sharing techniques and knowledge that span peptide synthesis, structural biology, cell-based assays, and preclinical evaluation. This cross-sectoral mobility helps build a European network of scientists skilled in peptide drug development. Early-career researchers gain exposure to both fundamental science and industrial translation, preparing them to lead future efforts in biopharmaceutical innovation. The exchange of expertise accelerates the pace of discovery and strengthens collaborative ties.

Dissemination of results is a key priority for the Inpact consortium, ensuring that scientific advances reach both the research community and the wider public. Peer-reviewed publications, conference presentations, and public engagement activities communicate the project's progress and findings. Books and papers generated through the collaboration contribute to the growing body of knowledge on peptide-based therapeutics. Patent filings protect intellectual property arising from the research, creating pathways toward commercial development. By maintaining transparency and sharing outcomes, the project aims to demonstrate the value of peptide innovation in addressing pressing health challenges.

Looking ahead, the Inpact project is positioned to influence the future of peptide-based medicine by establishing proof-of-concept for multifunctional therapeutics. The technology platform developed through this collaboration may serve as a foundation for new drug candidates that target diseases where current treatments fall short. Continued work on optimising peptide stability, delivery, and specificity will be essential for translating laboratory discoveries into clinical candidates. The partnership between academic research groups and pharmaceutical industry partners provides a pipeline for moving innovations from bench to bedside, with the ultimate goal of improving patient outcomes through smarter molecular design.